CERTARA Announces FY2022 Q4 Earnings Results as of December 31, 2022 on March 1, 2023.

Earnings report

CERTARA ($NASDAQ:CERT) recently reported its earnings results for FY2022 Q4 as of December 31, 2022 on March 1, 2023. According to the report, the company posted impressive growth figures during the fourth quarter. Total revenue rose by 194.5% compared to the same period of the previous year, reaching USD 9.2 million. Apart from that, net income also increased by 15.0% year over year, settling at USD 86.6 million.

The strong growth figures demonstrate CERTARA’s successful progress during the last year, indicating that the company’s strategies and investments are paying off. This is good news for shareholders of the company, and it is expected that the company will continue to build upon these positive results in the coming quarters.

Market Price

On Wednesday, March 1, 2023, CERTARA announced their financial results for the fourth quarter of their fiscal year 2022, which ended on December 31, 2022. At market open, CERTARA’s stock opened up at $18.3 and by market close it had closed at a price of $18.4, representing a 1.8% increase from the previous closing price of $18.1. This increase in stock price suggests investors responded positively to the financial results for the quarter. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Certara. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Certara. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Certara. More…

Key Ratios Snapshot

Some of the financial key ratios for Certara are shown below. More…

Analysis

GoodWhale is the perfect tool to analyze CERTARA‘s fundamentals and evaluate the risk involved with investing in its stock. We provide comprehensive financial analysis, allowing users to assess the risk of investing in CERTARA as well as other stocks. According to our Risk Rating, CERTARA is a high risk investment in financial and business aspects. GoodWhale’s analysis also reveals potential risks that may not be immediately visible from the fundamental data. We have detected two risk warnings in the balance sheet and cashflow statement of CERTARA that may affect its performance. If you are interested in seeing these potential risk factors, then become a registered user of GoodWhale and explore our comprehensive analysis! More…

Peers

The competition in the genomics market is heating up as Certara Inc goes up against 10x Genomics Inc, Cambridge Cognition Holdings PLC, and Schrodinger Inc. All four companies are vying for a piece of the market share in this rapidly growing industry. So far, Certara Inc has been the most successful, but the other three are not far behind.

– 10x Genomics Inc ($NASDAQ:TXG)

As of 2022, 10x Genomics Inc has a market cap of 2.93B. The company’s Return on Equity for that year was -10.81%. 10x Genomics is a company that provides sequencing and gene editing services.

– Cambridge Cognition Holdings PLC ($LSE:COG)

Cambridge Cognition Holdings PLC is a neuropsychological testing company. The company develops and commercializes cognitive tests used by clinicians and researchers to assess brain function in patients with neurological and psychiatric disorders. Cambridge Cognition’s tests are used in clinical trials to measure the efficacy of new treatments and to screen patients for clinical studies. The company’s products are also used by pharmaceutical companies to support marketing claims for cognitive enhancing drugs.

– Schrodinger Inc ($NASDAQ:SDGR)

Schrodinger Inc is a publicly traded company with a market capitalization of 1.55 billion as of 2022. The company has a return on equity of -15.16%. Schrodinger is a provider of advanced molecular simulations and enterprise software solutions. The company’s flagship product, Maestro, is a molecular modeling and simulation software platform used by scientists to predict the behavior of complex molecules and materials.

Summary

CERTARA is a leading life sciences service provider offering expertise in drug development, data analytics and biomedical simulation. In the fourth quarter of the year, CERTARA achieved a 194.5% increase in total revenue, reaching USD 9.2 million. Net income rose 15.0% compared to the same period the previous year, settling at USD 86.6 million. This significant performance highlights CERTARA’s exceptional ability to deliver profitable growth and provides investors with an excellent opportunity for investing in a reliable and proven industry leader.